INKT — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-13

• We are collaborating with Orphan Drug Consulting (ODC) to support physician-initiated requests for agenT-797 for individually identified patients. The program expands access for patients with serious unmet medical need and provides MiNK with program revenue for product supplied. Each request is init…

• Six Months Ended June 30, 2026 Compared to the Six Months Ended June 30, 2025

• Research and development (“R&D”) expense includes the costs associated with our internal research and development activities, including compensation and benefits, occupancy costs, manufacturing costs, costs of expert consultants, and administrative costs. There was no change in R&D expense for the s…

• General and administrative (“G&A”) expense consists primarily of personnel costs, facility expenses, and professional fees. G&A expense decreased 4% to $3.0 million for the six months ended June 30, 2026 from $3.1 million for the six months ended June 30, 2025. The decreased expense was primarily du…

• Other income, net increased to approximately $74,000 for the six months ended June 30, 2026 from $265,000 of other expense for the six months ended June 30, 2025, primarily due to foreign currency exchange losses in the three months ended June 30, 2025, compared to foreign currency exchange gains in…

Text removed vs the prior filing · source: 10-Q · 2026-05-15

• killing by T cells and was associated with depletion of immune suppressive FAP-expressing stellate cells and increased CD8+ T cell infiltration. Investigational new drug application (“IND”) enabling studies for MiNK-215 are underway.

• and development programs or the timing for bringing such programs to various markets or substantial partnering or out-licensing arrangements, and, therefore, when, if ever, material cash inflows are likely to commence.

• We have incurred annual operating losses since inception in 2017, and we had an accumulated deficit of $159.4 million as of March 31, 2026. We expect to incur losses over the next several years as we continue development of our technologies and product candidates, manage our regulatory processes, in…

• On July 15, 2025, we entered into a Sales Agreement with B. Riley Securities, Inc., as sales agent (the “Sales Agent”) to sell shares of our common stock, from time to time through the Sales Agent, at a maximum aggregate offering price of $50.0 million. The issuances and sales under the Sales Agreem…

• Our cash and cash equivalents balance as of March 31, 2026 was $9.5 million. Subsequent to the quarter end, we received $150,000 from the sales of common stock in at the market offerings. We believe that our cash and cash equivalents balance, plus anticipated funding, will be sufficient to satisfy o…

Text added vs the prior filing · source: 10-Q · 2026-08-13

• During the quarter ended June 30, 2026, none of our directors or executive officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each item is defined in Item 408 of Regulation S-K.

Text removed vs the prior filing · source: 10-Q · 2026-05-15

• On May 12, 2026, Austin Charette, Principal Accounting Officer of the Company, informed the Company he will be resigning effective May 29, 2026.

• During the quarter ended March 31, 2026, none of our directors or executive officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each item is defined in Item 408 of Regulation S-K.